Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,536 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Like Clear all
Active, not recruiting Not applicable Interventional

AIRB-4: Self-Determined Learning Model of Instruction

NCT04972851
View directory record Official record
Conditions
Autism Spectrum Disorder, Neurodevelopmental Disorders
Interventions
Self-Determined Learning Model of Instruction (SDLMI)
Behavioral
Lead sponsor
Health Resources and Services Administration (HRSA)
Federal
Eligibility
13 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Davis, California • Lawrence, Kansas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Not applicable Interventional Results available

Feasibility of Exercise and Spinal Cord Injury

NCT03941600
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Community-based Exercise Intervention group (CBE), Exercise Education Control group (EEG)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 22, 2026, 2:57 PM EDT
Terminated Not applicable Interventional Results available

High Flow Nasal Cannula Versus Bubble Nasal CPAP for the Treatment of Transient Tachypnea of the Newborn in Infants ≥ 35 Weeks Gestation

NCT01270581
View directory record Official record
Conditions
Transient Tachypnea of the Newborn
Interventions
High Flow Nasal Cannula, Bubble Nasal CPAP
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Up to 24 Hours
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PASOS: Improving the Health of Immigrant Workers

NCT02480244
View directory record Official record
Conditions
Overweight and Obesity, Diabetes
Interventions
Behavioral Intervention, Control
Behavioral · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Oxnard, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation for the Treatment of Traumatic Brain Injury

NCT02881151
View directory record Official record
Conditions
TBI (Traumatic Brain Injury)
Interventions
Deep brain stimulation
Device
Lead sponsor
Jaimie M. Henderson
Other
Eligibility
22 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 3 Interventional Results available

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

NCT02668653
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia
Interventions
Chemotherapy, Quizartinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
11
States / cities
Gainesville, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

NCT00158743
View directory record Official record
Conditions
Pre-eclampsia
Interventions
Anti-digoxin antibody (FAB fragment), sodium chloride
Drug · Other
Lead sponsor
BTG International Inc.
Other
Eligibility
Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Mobile, Alabama • Phoenix, Arizona • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 22, 2026, 2:57 PM EDT
Recruiting Not applicable Interventional

Analgesic Response to Opioids in Patients With Fibromyalgia After Conventional Acupuncture Versus Sham Acupuncture

NCT06571110
View directory record Official record
Conditions
Fibromyalgia
Interventions
Traditional Acupuncture, Sham Acupuncture
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin D Inadequacy in Rural Populations, Evaluation of Correction by Food Supplementation

NCT00690417
View directory record Official record
Conditions
Vitamin D Insufficiency, Vitamin D Deficiency
Interventions
Cholecalciferol (vitamin D3)
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 22, 2026, 2:57 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Motivational Refinements for Facilitating Reinforcement Schedule Thinning

NCT05790668
View directory record Official record
Conditions
Decreasing Destructive Behavior, Increasing Functional Communicative Behavior
Interventions
Traditional Schedule Thinning, PIA-Informed Schedule Thinning, PIA-Informed Schedule Thinning with Competing Stimuli
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
3 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
2
States / cities
New Brunswick, New Jersey • Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease

NCT00325078
View directory record Official record
Conditions
Chronic Granulomatous Disease, Crohn'S-like IBD, Inflammatory Bowel Disease (IBD)
Interventions
Infliximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Oct 22, 2026, 2:57 PM EDT
Terminated Phase 3 Interventional Results available

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

NCT04927247
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 22, 2026, 2:57 PM EDT
Recruiting Not applicable Interventional

Motivational Interviewing at Intake vs Intake as Usual on Client Engagement in Addiction Treatment

NCT05489068
View directory record Official record
Conditions
Substance-Related Disorders, Treatment Adherence
Interventions
Motivational Interviewing at Intake (MII), Intake as Usual (IAU)
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Teen Access to Sexual and Mental Health Care

NCT05444855
View directory record Official record
Conditions
Health Care Utilization
Interventions
Peer Leader Model
Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
14 Years to 100 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 2:57 PM EDT
Terminated Phase 3 Interventional Results available

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

NCT01510184
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma
Interventions
Zevalin, Y-90-Zevalin, Rituximab, In-111 Zevalin
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
60 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
28
States / cities
Casa Grande, Arizona • Berkeley, California • Duarte, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 22, 2026, 2:57 PM EDT
Not yet recruiting Not applicable Interventional

Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1

NCT07701460
View directory record Official record
Conditions
Weight Maintenance
Interventions
Digital Behavioral Application
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

AI-Based Fidelity Feedback to Enhance CBT

NCT05340738
View directory record Official record
Conditions
Cognitive Behavioral Therapy, Therapy
Interventions
LyssnCBT
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

NCT02445391
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Capecitabine, Carboplatin, Cisplatin
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1023
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nonrandomized Evaluation of a Multidimensional Behavioral Intervention

NCT03717597
View directory record Official record
Conditions
Subjective Cognitive Concerns (SCC)
Interventions
Intervention
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
65 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 22, 2026, 2:57 PM EDT
Completed No phase listed Observational Results available

Evaluation of Moderate to Severe Influenza Outcomes in Children

NCT02979626
View directory record Official record
Conditions
Influenza, Otitis Media, Lower Resp Tract Infection, Encephalitic Infection, Myositis Viral, Fever
Interventions
Respiratory nasal swab
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Months to 8 Years
Enrollment
1,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Aurora, Colorado • Broomfield, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 22, 2026, 2:57 PM EDT
Recruiting Phase 2 Interventional

Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

NCT07573163
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status
Interventions
Tirzepatide, Standard medical treatment
Drug · Other
Lead sponsor
Alaa Sada
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

NCT02782546
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Graft cell infusion, Tacrolimus, Mycophenolate mofetil, G-CSF, CIML NK cell infusion, ALT-803, Leukapheresis
Procedure · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 2:57 PM EDT
Completed No phase listed Observational

Monitoring Of Scratch Via Accelerometry In Children

NCT03873220
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Wrist Actigraphy Devices, Sleep Monitor, Polysomnography, Videography
Device
Lead sponsor
Boston University
Other
Eligibility
2 Years to 11 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 22, 2026, 2:57 PM EDT
Recruiting Phase 1 Interventional

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT05143996
View directory record Official record
Conditions
Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
CLN-049
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 22, 2026, 2:57 PM EDT